Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

59.82
+0.38000.64%
Pre-market: 59.67-0.1500-0.25%08:40 EST
Volume:9.71M
Turnover:581.18M
Market Cap:121.39B
PE:-13.55
High:60.26
Open:59.43
Low:59.38
Close:59.44
Loading ...

Bristol-Myers Squibb Co - FDA Assigns Target Action Date of June 23, 2025

THOMSON REUTERS
·
24 Feb

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients With Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

THOMSON REUTERS
·
24 Feb

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Business Wire
·
24 Feb

Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus

Zacks
·
22 Feb

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Benzinga
·
22 Feb

Bristol-Myers Squibb: Balancing Growth and Challenges Amidst Market Dynamics – A Hold Recommendation

TIPRANKS
·
21 Feb

Bristol-Myers Squibb (BMY) Gets a Hold from Bernstein

TIPRANKS
·
21 Feb

Bristol-Myers Squibb (BMY) Receives a Buy from Truist Financial

TIPRANKS
·
20 Feb

Bioarctic Says Global License Agreement With Bristol Myers Squibb For Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance And Closing

Reuters
·
20 Feb

Bristol Myers Squibb Co. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
20 Feb

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

Benzinga
·
20 Feb

Bristol-Myers Squibb's Lung Cancer Drug Shows Significant Increase in Patients' Overall Survival

MT Newswires Live
·
19 Feb

BRIEF-Bristol Myers Squibb Announces Opdivo Plus Chemotherapy As The Only Therapy To Demonstrate Overall Survival In Resectable Non-Small Cell Lung Cancer

Reuters
·
19 Feb

Bristol Myers announces OS from Phase 3 CheckMate -816 study

TIPRANKS
·
19 Feb

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

THOMSON REUTERS
·
19 Feb

Bristol-Myers Squibb Co - No New Safety Signals Observed With Opdivo Plus Chemotherapy

THOMSON REUTERS
·
19 Feb